Votrient 400mg Tablet

• Advanced Renal Cell Carcinoma (RCC)
• Soft Tissue Sarcoma (STS)

Votrient 400mg tablet has several side effects, which are given below. If the below-mentioned symptoms are seen in the patients and are not tolerable, immediately consult the doctor.

• Bleeding risks
• Headache
• Breathing problem
• Pain in the bone, joints & muscles
  
• Change in taste
• Hair color change
• Skin pigmentation 
• Low appetite
• Irregular heartbeat
• Vomiting
• Diarrhea
• Fatigue
• Nausea
• Hypertension 
  
• Increased sugar levels
• Hepatotoxicity

• You have to follow the doctor's prescription strictly for better results.
• Swallow it as a whole.
• Do not chew, crush, or break it.
• Votrient 400mg Tablet is to be taken on an empty stomach.

• Votrient (pazopanib) 400 mg works by blocking certain proteins called tyrosine kinases that help tumors grow new blood vessels.
• By inhibiting these pathways, it reduces blood supply to the tumor, slowing its growth and spread.
  

• ​In case you missed any dose, consult your doctor.
• Swallow Votrient 400 mg whole on an empty stomach; do not chew, crush, or break the tablet.
• Do not take twice the dose to catch up on the missed dose. This will cause severe side effects and impact your overall health.​
  

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Kwon, J. H., Lee, S. E., Choi, J. Y., Kim, H. Y., & Park, S. H. (2024). Real-world outcomes of pazopanib in advanced soft tissue sarcoma: A multicenter study in Korea. Cancer Medicine, 13(5), 2173–2182 - https://pubmed.ncbi.nlm.nih.gov/32607656/
• Ravaud, A., Motzer, R. J., & Sternberg, C. N. (2023). Long-term safety of pazopanib in advanced renal cell carcinoma: A pooled analysis of clinical trial data. Clinical Genitourinary Cancer, 21(2), e137–e145.
• Singh, A., Mehra, N., & Kapoor, A. (2023). Comparative safety and efficacy of pazopanib versus sunitinib in metastatic renal cell carcinoma: A meta-analysis. Journal of Oncology Pharmacy Practice, 29(4), 301–309 - https://pubmed.ncbi.nlm.nih.gov/39257075/
• Tan, A. R., Weiss, G. J., Bilen, M. A., Sonpavde, G., & George, S. (2023). Pharmacokinetics and exposure–response relationship of pazopanib in patients with renal cell carcinoma and sarcoma. Clinical Pharmacokinetics, 62(3), 347–358.
• Van Der Graaf, W. T., Gelderblom, H., & Mathijssen, R. H. J. (2024). Does individualization of pazopanib in soft tissue sarcoma: The case for therapeutic drug monitoring? European Journal of Cancer, 190, 1–9.
• Verheijen, R. B., Lolkema, M. P. J., de Bruijn, P., et al. (2024). Optimizing pazopanib dosing: Evaluation of reduced-dose strategies in oncology patients. British Journal of Clinical Pharmacology, 90(2), 389–400 - https://pmc.ncbi.nlm.nih.gov/articles/PMC5595974/